The Charter of the Prix Galien UK Committee
The Prix Galien rewards excellence and novelty, and awards additional honors to those who show great promise in the fields of innovative therapeutics, and who have served humanity at large.
The pharmaceutical, biotechnology, medical technology and digital health products considered for the Prix Galien UK Award shall have been based on innovative science, developed by synthetic chemistry or molecular biology, manufactured to precise specifications, tested in controlled clinical trials and marketed by ethical pharmaceutical companies.
The committee will award four prizes for therapeutics:
The Best Pharmaceutical Product
The UK Prix Galien Award for Best Pharmaceutical Product is open to any medicine that has been developed to prevent, cure and/or treat disease that has had a significant, positive impact on improving patient lives.
• Products must have received marketing approval between December 31, 2016 – December 31, 2021 (unless the award is for a new/innovative indication added during that period)
• We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights.
The Best Biotechnology Product
The UK Prix Galien Award for the Best Biotechnology Product is open to any biologic medicine (for example – vaccines, ATMPs, recombinant proteins, monoclonal antibodies) that has had a significant, positive impact on improving patient lives.
• Products must have received marketing approval between December 31, 2016 – December 31, 2021 (unless the award is for a new/innovative indication added during that period)
• We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights.
The Best Medical Technology Product
The UK Prix Galien Award for Best Medical Technology Product is open to any instrument, apparatus, appliance, software, material or other article (whether used alone or in combination together with any accessories, including software used specifically for diagnostic and/or therapeutic purposes) that has had a significant, positive impact on improving patient lives.
• Products granted a CE mark between December 31, 2016 – December 31, 2021 (5-year period)
• We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights.
The Best Digital Health Solution
The UK Prix Galien Award for the Best Digital Health Solution is open to any evidenced-based digital product that has demonstrated a significant, positive impact on improving patient lives.
• Products must be clinically validated (minimum 2 peer reviewed papers) or have been approved by the MHRA
• Evidence of sustained growth and patient satisfaction over the past three years
• Revenue Based > £350K in the past 12 months
• At least 10 or more employees at the start of the period
*3 criteria must be met to be eligible.
• We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights
Awarding the prizes
The prizes will be awarded for application of life sciences that improve the human condition, principally based on three criteria:
1. What was innovative in the course of this product’s scientific development, application or clinical utility?
2. What was learned for the future of biomedical science from this product’s introduction to the clinic?
3. What impact has the product had on human health?
Criteria that will not be considered are the size of the market, the cost of development or the contingencies of distribution. The Committee has the right to not select a winner in a particular year.
Other new awards, consistent with the mission of the Galien Foundation, are planned. At the discretion of the committee, these awards will be judged by the committee members.
The awards committee will be composed of up to thirteen individuals. Except at the onset, committee members will generally serve for one, or a maximum of two, five-year terms. Membership terms will be staggered to ensure optimal transition. Members will be highly distinguished individuals from the scientific research and business communities, primarily from the UK. In addition to outstanding academic credentials, committee members must have demonstrated expertise and understanding of human therapeutics and must be familiar with global healthcare issues. The Board, in consultation with the committee, will choose a Chair, who will serve for one, or a maximum of two seven-year terms.
The Board will entertain nominations for the committee from current committee members, former committee members, the academic and research communities, and from the scientific divisions of companies engaged in the development of human therapeutics.
The decisions of the independent committee with respect to the selection of winners for awards will be final and wholly the decision of the committee. The committee deliberations will be conducted in private, and without any input whatsoever from the Board of the Foundation, or from Member organizations or other sponsors.